Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Imitrex Patent Settlement Allows For Entry During Pediatric Exclusivity Period

This article was originally published in The Pink Sheet Daily

Executive Summary

Spectrum/Par say launch of subcutaneous sumatriptan could come as early as Aug. 6, 2008.
Advertisement

Related Content

GSK/Pozen Win Long-awaited Approval For Combo Migraine Drug
GSK/Pozen Win Long-awaited Approval For Combo Migraine Drug
Pozen/GlaxoSmithKline’s Trexima Gets Second FDA Approvable Letter
Pozen/GlaxoSmithKline’s Trexima Gets Second FDA Approvable Letter
GSK/Pozen To Reformat Trexima Clinical Trial Data
Latest Imitrex Patent Settlement Protects GSK’s “Authorized” Generic
Imitrex "Authorized" Generic Launch Planned In Q4 2008
Imitrex "Authorized" Generic Launch Planned In Q4 2008
GlaxoSmithKline/Pozen Anticipate Mid-2007 Launch For Trexima Migraine Combo
Par To Market Generic Imitrex Through Deal With Spectrum

Topics

Advertisement
UsernamePublicRestriction

Register

PS063361

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel